ATAtai Life Sciences N.V. ATAI · NASDAQ
$7.35 +0.68% (+$0.05)
- Market cap
- $2.72B
- Enterprise value
- $2.55B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 607.9x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -61.3%
- Bruto marža
- 86.3%
- Neto marža
- -14,938.4%
- Dividend yield
- 91.84%
- Payout ratio
- -
- Neto dolg/EBITDA
- -
- Beta
- 1.55
- Free float
- 54.2%
O podjetju
Atai Life Sciences N.V. (ATAI) is a biotechnology company focused on research and development of novel therapeutic approaches in the field of mental health and psychiatric disorders. The company focuses on innovative therapies and drugs that have the potential to treat or improve the lives of people suffering from various mental illnesses, including depression, anxiety, post-traumatic stress disorder, addictions, and other disorders. Atai Life Sciences actively collaborates with other research institutions and biotechnology companies and invests in projects with the hope of discovering new treatment options. Their goal is to bring new drugs and therapies to the market that can make a significant difference for patients with mental disorders. Atai Life Sciences N.V. (ATAI) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focusing on innovative therapeutic approaches in the field of mental health.
Sector
Healthcare
Industry
Biotechnology
CEO
Srinivas G. Rao
Employees
99
Headquarters
New York
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
- Kaj govori v prid: Prihodki so v zadnjih 3 letih rasli za 160 % letno.
- Na kaj bodite pozorni: Analitiki v tem poslovnem letu pričakujejo padec prihodkov za 47 %.
- Na kaj bodite pozorni: Napovedi dobička ni dosegla 4-krat v zadnjih 8 četrtletjih.
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
- Na kaj bodite pozorni: Podjetje je v zadnjih 12 mesecih poslovalo z izgubo.
Finančno zdravje
Ali zmore svoj dolg?
- Kaj govori v prid: Ima več denarja kot dolga: $168,8M proti $4,29M.
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke